Evaluation of the Information Letter to Relatives in the Context of Genetic Assessments

NCT ID: NCT02636543

Last Updated: 2015-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

325 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The decree of June 20th 2013 (n° 2013-527) suggests a protocol regarding the transmission of information to the relatives after genetic diagnosis of a serious condition. This decree includes a specific model of letter that can be sent to relatives by genetic professionals. We evaluated the understanding and feelings after the reading of the decree's letter (letter A) on patients and the public. A focus group drafted a new version of the letter (letter B) through these observations. The two letter models (A vs B) are compared in terms of impact through precise items (understanding and feelings) on three populations: patients, public and genetic professionals. Assumption is made that the letter B will be preferred to the letter A. Overall, we aim at giving a letter formulation accommodating as many people as possible to standardize practices.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The recent publication of the decree of June 20th 2013 (n° 2013-527) suggests a protocol regarding the transmission of information of the relatives after genetic diagnosis of a serious condition allowing preventative or care measures. In the case a mutation career refuses to directly inform other members of his family, option is to call on services of a genetic professional for the transmission of its family information. This decree includes a specific model of letter that can be sent to relatives by genetic professionals.

The main objective of the present study is the standardization of the procedure concerning the information to relatives by all genetic professionals. It would allow the same format of information in all families involved.

The first part (study 1a) evaluated the understanding and feelings after the reading of the decree's letter (letter A) on patients and the public, through the use of an individual and oral questionnaire. Interviews with the patients, public, genetic professionals and people who have received this letter completed the study 1a (study 1b). A focus group (accounting different genetic professionals and patient associations) composed a new version of letter (letter B) through these observations (study 1c).

The second part will compare the two letters model (A vs B) impact through precise items on three populations: patients, public and genetic professionals. This study will allow to:

* Evaluate how the letter composed by the focus group (letter A) is understood and perceived by the patients and the public with the same methodology as study 1a (study 2a) ;
* Compare the two letters model (A vs B) to describing the preference of patients, public and genetic professionals (study 2b).

The expected results would help us to choose the letter accommodating as many people as possible to standardize practices.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transmission of Information to the Relatives After Genetic Diagnosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

genetic diagnosis information letter model

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 2a-patient

75 patients who attended a genetic counselling consultation.

Questionnaire after the reading of letter B.

Intervention Type OTHER

Oral questionnaire after the reading of letter B.

Group 2a-public

75 persons belonging to general population.

Questionnaire after the reading of letter B.

Intervention Type OTHER

Oral questionnaire after the reading of letter B.

Group 2b-patient

75 patients who attended a genetic counselling consultation (those patients are different than patients from group 2a-).

Questionnaire after the reading of letter B.

Intervention Type OTHER

Oral questionnaire after the reading of letter B.

Questionnaire after the reading of letters A and B

Intervention Type OTHER

Oral questionnaire after the reading of letters A and B during individual interview.

Group 2b-public

75 persons belonging to general population (those persons are different than patients from group 2a).

Questionnaire after the reading of letter B.

Intervention Type OTHER

Oral questionnaire after the reading of letter B.

Questionnaire after the reading of letters A and B

Intervention Type OTHER

Oral questionnaire after the reading of letters A and B during individual interview.

Group 2b-professional

75 genetic professionals.

Questionnaire after the reading of letter B.

Intervention Type OTHER

Oral questionnaire after the reading of letter B.

Questionnaire after the reading of letters A and B

Intervention Type OTHER

Oral questionnaire after the reading of letters A and B during individual interview.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire after the reading of letter B.

Oral questionnaire after the reading of letter B.

Intervention Type OTHER

Questionnaire after the reading of letters A and B

Oral questionnaire after the reading of letters A and B during individual interview.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years old and above
* French native speaker
* informed person
* person whose non-opposition has been received
* public: person who never attended a genetic counselling consultation
* professional: geneticist and genetic counsellors working in France

Exclusion Criteria

* study 2a : person who took part of study 2b
* study 2b : person who took part of study 2a
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Bordeaux

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cécile ZORDAN, Ms

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Bordeaux

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Bordeaux

Bordeaux, Aquitaine, France

Site Status

Hôpital Universitaire de Strasbourg

Strasbourg, Aquitaine, France

Site Status

CHRU de Montpellier - Hôpital Arnaud de Villeneuve

Montpellier, , France

Site Status

CHU de Rennes - Hôpital SUD

Rennes, , France

Site Status

CHU de Toulouse - Hôpital Purpan

Toulouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHUBX 2014/32

Identifier Type: -

Identifier Source: org_study_id